Back to research

Research paper

Cannabidiol (CBD) and cognition in epilepsy

Review of CBD's effects on cognition in epilepsy. CBD suppresses neuronal excitability while providing neuroprotective and anti-inflammatory benefits. Cognitive effects are neutral to modestly beneficial - CBD does not carry the cognitive-burden profile of many traditional ASMs. Mechanisms include endocannabinoid modulation, inflammatory signaling suppression, and potential antioxidant effects.

Indexed context

Gaston TE, et al.

cannabidiolcbdcognitionepilepsyanti-inflammatory

Markdown path

content/research/papers/2021-gaston-cbd-cognition-epilepsy.md

Findings

Review of CBD's effects on cognition in epilepsy. CBD suppresses neuronal excitability while providing neuroprotective and anti-inflammatory benefits. Cognitive effects are neutral to modestly beneficial - CBD does not carry the cognitive-burden profile of many traditional ASMs. Mechanisms include endocannabinoid modulation, inflammatory signaling suppression, and potential antioxidant effects.

Why it may matter for Levi

Plausible contingent treatment option for Levi, particularly if (a) TBRS or another chromatinopathy is ever confirmed (per Datta 2026), (b) the immune-inflammatory hypothesis continues to carry weight, and (c) conventional ASM escalation is needed. CBD (Epidiolex) has FDA approval in TSC, Dravet, and LGS - not specifically DEE-SWAS - so use in Levi would be off-label. Cognition-neutral profile is a meaningful advantage over traditional ASMs for long-term maintenance.

Paper text

Gaston et al. (2021) — CBD and cognition in epilepsy

Source

Why this paper is in the corpus

Review of cannabidiol's effects on cognition in epilepsy, framing CBD as both a seizure-suppressing and a potentially neuroprotective / anti-inflammatory agent. Relevant given the 2026 Datta case report (already in the corpus) showing CBD response in TBRS-associated EE-SWAS.

Key findings

  • CBD suppresses neuronal excitability while providing neuroprotective and anti-inflammatory benefits.
  • Cognitive effects in epilepsy cohorts are generally neutral to modestly beneficial; CBD does not appear to carry the cognitive-burden profile of many traditional ASMs.
  • Mechanisms include modulation of the endocannabinoid system, suppression of inflammatory signaling, and potential antioxidant effects.
  • Particularly relevant for epileptic conditions with immune involvement.

Levi-relevant takeaways

  • CBD remains a plausible contingent treatment option for Levi, particularly if (a) TBRS or another chromatinopathy is ever confirmed (per Datta 2026), (b) the immune-inflammatory hypothesis continues to carry weight, and (c) conventional ASM escalation is needed.
  • Not a first-line DEE-SWAS option. CBD (Epidiolex) has FDA approval in the US for TSC, Dravet, and Lennox-Gastaut — not specifically DEE-SWAS — so use in Levi would be off-label in that indication.
  • The cognition-neutral profile is a meaningful advantage over traditional ASMs if long-term maintenance therapy is eventually needed.

Citation note

Referenced as [30] in the 2026-04-21 user-supplied comprehensive DEE-SWAS / ESES / CSWS research report. Companion paper to the Datta 2026 TBRS-EE-SWAS case report (2026-datta-tbrs-eeswas-cannabidiol.md).